Cost-effectiveness of using electron beam computed tomography to identify patients at risk for clinical coronary artery disease.

[1]  L H Kuller,et al.  Epidemiology of cardiovascular diseases: current perspectives. , 1976, American journal of epidemiology.

[2]  G. Rose,et al.  Self-administration of a questionnaire on chest pain and intermittent claudication. , 1977, British journal of preventive & social medicine.

[3]  G. Torrance,et al.  The utility of different health states as perceived by the general public. , 1978, Journal of chronic diseases.

[4]  S B Foote,et al.  Assessing medical technology assessment: past, present, and future. , 1987, The Milbank quarterly.

[5]  C. Jenkins.  Epidemiology of cardiovascular diseases. , 1988, Journal of consulting and clinical psychology.

[6]  A. Stewart,et al.  Functional status and well-being of patients with chronic conditions. Results from the Medical Outcomes Study. , 1989, JAMA.

[7]  B Littenberg,et al.  The role of exercise testing in screening for coronary artery disease. , 1989, Annals of internal medicine.

[8]  A S Detsky,et al.  How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. , 1992, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[9]  R. Klein,et al.  The Beaver Dam Health Outcomes study , 1993, Medical decision making : an international journal of the Society for Medical Decision Making.

[10]  D K Owens,et al.  Cost-effectiveness of warfarin and aspirin for prophylaxis of stroke in patients with nonvalvular atrial fibrillation. , 1995, JAMA.

[11]  Marshall Kg,et al.  Prevention. How much harm? How much benefit? 3. Physical, psychological and social harm , 1996 .

[12]  M. Weinstein,et al.  Recommendations of the Panel on Cost-effectiveness in Health and Medicine. , 1996, JAMA.

[13]  G. Diamond,et al.  Does coronary artery screening by electron beam computed tomography motivate potentially beneficial lifestyle behaviors? , 1996, The American journal of cardiology.

[14]  Alan D. Lopez,et al.  The global burden of disease: a comprehensive assessment of mortality and disability from diseases injuries and risk factors in 1990 and projected to 2020. , 1996 .

[15]  M A Hlatky,et al.  Task force 6: cost effectiveness of assessment and management of risk factors , 1996 .

[16]  L. Goldman,et al.  The recent decline in mortality from coronary heart disease, 1980-1990. The effect of secular trends in risk factors and treatment. , 1997, JAMA.

[17]  D. Levy,et al.  Prediction of coronary heart disease using risk factor categories. , 1998, Circulation.

[18]  P. O'Malley,et al.  Self-referral of patients for electron-beam computed tomography to screen for coronary artery disease. , 1998, The New England journal of medicine.

[19]  Cost Effectiveness of Intensive Treatment of Hypertension , 1998 .

[20]  R. Caterina,et al.  A cost-effectiveness analysis of aspirin versus oral anticoagulants after acute myocardial infarction in Italy -- equivalence of costs as a possible case for oral anticoagulants. , 1998, Thrombosis and haemostasis.

[21]  L. Coupal,et al.  Estimating the benefits of modifying risk factors of cardiovascular disease: a comparison of primary vs secondary prevention. , 1998, Archives of internal medicine.

[22]  Harlan M. Krumholz,et al.  Do “America's Best Hospitals” Perform Better for Acute Myocardial Infarction? , 1999 .

[23]  L E Ginzton,et al.  Coronary calcium does not accurately predict near-term future coronary events in high-risk adults. , 1999, Circulation.

[24]  M. Rich,et al.  Cost-effectiveness analysis in clinical practice: the case of heart failure. , 1999, Archives of internal medicine.

[25]  R. Detrano,et al.  Prognostic value of coronary electron-beam computed tomography for coronary heart disease events in asymptomatic populations. , 2000, The American journal of cardiology.

[26]  S. Yusuf,et al.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. , 2000 .

[27]  L. Prosser,et al.  Cost-Effectiveness of Cholesterol-Lowering Therapies according to Selected Patient Characteristics , 2000, Annals of Internal Medicine.

[28]  A. Gotto,et al.  Effect of lovastatin on cardiovascular resource utilization and costs in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). AFCAPS/TexCAPS Research Group. , 2000, The American journal of cardiology.

[29]  J. Larosa,et al.  Enhancing drug compliance in lipid-lowering treatment. , 2000, Archives of family medicine.

[30]  P. O'Malley,et al.  Do conventional risk factors predict subclinical coronary artery disease? Results from the Prospective Army Coronary Calcium Project. , 2001, American heart journal.

[31]  R. Beaglehole,et al.  The real contribution of the major risk factors to the coronary epidemics: time to end the "only-50%" myth. , 2001, Archives of internal medicine.

[32]  B. O'brien,et al.  Cost-effectiveness of beta-blocker therapy with metoprolol or with carvedilol for treatment of heart failure in Canada. , 2001, American heart journal.

[33]  R. Brant,et al.  A randomized, controlled trial of the use of pulmonary-artery catheters in high-risk surgical patients. , 2003, The New England journal of medicine.

[34]  R. Detrano,et al.  Coronary artery calcium score combined with Framingham score for risk prediction in asymptomatic individuals. , 2004, JAMA.